Strategies to therapeutically modulate cytokine action

1. Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150–159 (1974).

   Article 
   CAS 
   PubMed 

   Google Scholar 

2. Keegan, A. D. & Leonard, W. J. in Paul’s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh, N. J. & Holland, S. M.) 258–307 (Wolters Kluwer, 2023).

3. Isaacs, A. & Lindenmann, J. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258–267 (1957).

   CAS 
   PubMed 

   Google Scholar 

4. Decker, T., Muller, M. & Stockinger, S. The Yin and Yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 5, 675–687 (2005).

   Article 
   CAS 
   PubMed 

   Google Scholar 

5. Wheelock, E. F. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 149, 310–311 (1965).

   Article 
   CAS 
   PubMed 

   Google Scholar 

6. Billiau, A. & Matthys, P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 20, 97–113 (2009).

   Article 
   CAS 
   PubMed 

   Google Scholar 

7. Chen, J. et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111, 5163–5172 (2008).

   Article 
   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

8. Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).

   Article 
   CAS 
   PubMed 

   Google Scholar 

9. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).

   Article 
   CAS 
   PubMed 

   Google Scholar 

10. Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387–397 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

11. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

12. Hernandez, R., Poder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614–628 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

13. Holder, P. G. et al. Engineering interferons and interleukins for cancer immunotherapy. Adv. Drug Deliv. Rev. 182, 114112 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

14. Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21–37 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

15. Raeber, M. E., Sahin, D. & Boyman, O. Interleukin-2-based therapies in cancer. Sci. Transl. Med. 14, eabo5409 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

16. Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237–253 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

17. Wlodawer, A., Pavlovsky, A. & Gustchina, A. Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding. Protein Sci. 2, 1373–1382 (1993).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

18. Goel, R. R., Kotenko, S. V. & Kaplan, M. J. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 17, 349–362 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

19. Dinarello, C. A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat. Rev. Rheumatol. 15, 612–632 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

20. Nold, M. F. et al. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014–1022 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

21. Nold-Petry, C. A. et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat. Immunol. 16, 354–365 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

22. van de Veerdonk, F. L. et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl Acad. Sci. USA 109, 3001–3005 (2012).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

23. Mora, J. et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J. Mol. Cell Biol. 8, 426–438 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

24. de Graaf, D. M., Teufel, L. U., Joosten, L. A. B. & Dinarello, C. A. Interleukin-38 in health and disease. Cytokine 152, 155824 (2022).

    Article 
    PubMed 

    Google Scholar 

25. Majumder, S. & McGeachy, M. J. IL-17 in the pathogenesis of disease: good intentions gone awry. Annu. Rev. Immunol. 39, 537–556 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

26. Mills, K. H. G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23, 38–54 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

27. Wilson, S. C. et al. Organizing structural principles of the IL-17 ligand-receptor axis. Nature 609, 622–629 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

28. Murray-Rust, J. et al. Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors. Structure 1, 153–159 (1993).

    Article 
    CAS 
    PubMed 

    Google Scholar 

29. Monin, L. & Gaffen, S. L. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb. Perspect. Biol. 10, a028522 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

30. Wallach, D. The tumor necrosis factor family: family conventions and private idiosyncrasies. Cold Spring Harb. Perspect. Biol. 10, a028431 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

31. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306–312 (1992). Provides the structure of a type I cytokine–type I cytokine receptor complex, revealing receptor homodimerization for the growth hormone system.

    Article 
    PubMed 

    Google Scholar 

32. Bazan, J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl Acad. Sci. USA 87, 6934–6938 (1990).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

33. Wang, X., Lupardus, P., Laporte, S. L. & Garcia, K. C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27, 29–60 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

34. Spolski, R., Gromer, D. & Leonard, W. J. The gamma c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response. F1000Res 6, 1872 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

35. Lin, J. X. & Leonard, W. J. The common cytokine receptor gamma chain family of cytokines. Cold Spring Harb. Perspect. Biol. 10, a028449 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

36. Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

37. Leonard, W. J., Lin, J. X. & O’Shea, J. J. The γc family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832–850 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

38. Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N. & Garcia, K. C. The structure of interleukin-2 complexed with its alpha receptor. Science 308, 1477–1480 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

39. Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147–157 (1993). Demonstrates that IL-2Rγ mutations result in X-SCID and predicted the existence of the γ_c family of cytokines.

    Article 
    CAS 
    PubMed 

    Google Scholar 

40. Leonard, W. J. The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 47, 229–239 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

41. Fischer, A., Notarangelo, L. D., Neven, B., Cavazzana, M. & Puck, J. M. Severe combined immunodeficiencies and related disorders. Nat. Rev. Dis. Prim. 1, 15061 (2015).

    Article 
    PubMed 

    Google Scholar 

42. Gonnord, P. et al. A hierarchy of affinities between cytokine receptors and the common gamma chain leads to pathway cross-talk. Sci. Signal. 11, eaal1253 (2018).

    Article 
    PubMed 

    Google Scholar 

43. Paul, W. E. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell 57, 521–524 (1989).

    Article 
    CAS 
    PubMed 

    Google Scholar 

44. Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355–29358 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar 

45. Nekoui, A. & Blaise, G. Erythropoietin and nonhematopoietic effects. Am. J. Med. Sci. 353, 76–81 (2017).

    Article 
    PubMed 

    Google Scholar 

46. Cote-Sierra, J. et al. Interleukin 2 plays a central role in Th2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880–3885 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

47. Liao, W. et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor α-chain expression. Nat. Immunol. 9, 1288–1296 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

48. Liao, W., Lin, J. X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12, 551–559 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

49. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

50. Liao, W. et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc. Natl Acad. Sci. USA 111, 3508–3513 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

51. Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

52. Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).

    Article 
    PubMed 

    Google Scholar 

53. Kolios, A. G. A., Tsokos, G. C. & Klatzmann, D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat. Rev. Rheumatol. 17, 749–766 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

54. Waldmann, T. A., Waldmann, R., Lin, J.-X. & Leonard, W. J. The implications of IL-15 trans-presentation on the immune response. Adv. Immunol. 156, 103–132 (2022).

    Article 
    PubMed 

    Google Scholar 

55. Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T⁻B⁺NK⁺ severe combined immunodeficiency. Nat. Genet. 20, 394–397 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

56. Keegan, A. D., Leonard, W. J. & Zhu, J. Recent advances in understanding the role of IL-4 signaling. Fac. Rev. 10, 71 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

57. Hara, T. & Miyajima, A. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J. 11, 1875–1884 (1992).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

58. Nakamura, Y. et al. Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling. Nature 369, 330–333 (1994). With ref. 59, one of two papers demonstrating that IL-2 signalling requires the dimerization of the IL-2Rβ and γ_c cytoplasmic domains. Such dimerization has informed strategies related to IL-2 therapy.

    Article 
    CAS 
    PubMed 

    Google Scholar 

59. Nelson, B. H., Lord, J. D. & Greenberg, P. D. Cytoplasmic domains of the interleukin-2 receptor β and γchains mediate the signal for T-cell proliferation. Nature 369, 333–336 (1994). With ref. 58, one of two papers demonstrating that IL-2 signalling requires the dimerization of the IL-2Rβ and γ_c cytoplasmic domains. Such dimerization has informed strategies related to IL-2 therapy.

    Article 
    CAS 
    PubMed 

    Google Scholar 

60. Leonard, W. J. & O’Shea, J. J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293–322 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

61. Moraga, I. et al. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6, e22882 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

62. Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

63. Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797–800 (1995). Predicts that JAK3 inhibitors would be immunosuppressive, helping to launch the field of development of JAK inhibitors.

    Article 
    CAS 
    PubMed 

    Google Scholar 

64. Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745–755 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar 

65. Li, Z., Rotival, M., Patin, E., Michel, F. & Pellegrini, S. Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage. PLoS ONE 15, e0225289 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

66. Migone, T. S. et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79–81 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

67. Danial, N. N., Pernis, A. & Rothman, P. B. Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875–1877 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

68. Levine, R. L. & Gilliland, D. G. JAK-2 mutations and their relevance to myeloproliferative disease. Curr. Opin. Hematol. 14, 43–47 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

69. Sathyanarayana, B. K., Li, P., Lin, J. X., Leonard, W. J. & Lee, B. Molecular models of STAT5A tetramers complexed to DNA predict relative genome-wide frequencies of the spacing between the two dimer binding motifs of the tetramer binding sites. PLoS ONE 11, e0160339 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

70. Begitt, A. et al. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. 15, 168–176 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar 

71. Lin, J. X. et al. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36, 586–599 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

72. Lin, J. X. et al. Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells. Nat. Commun. 8, 1320 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

73. Monaghan, K. L. et al. Tetramerization of STAT5 promotes autoimmune-mediated neuroinflammation. Proc. Natl Acad. Sci. USA 118, e2116256118 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

74. Friedmann, M. C., Migone, T. S., Russell, S. M. & Leonard, W. J. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc. Natl Acad. Sci. USA 93, 2077–2082 (1996).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

75. Lin, J. X. et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331–339 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

76. Zeng, R. et al. The molecular basis of IL-21–mediated proliferation. Blood 109, 4135–4142 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

77. Migone, T. S. et al. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol. Cell Biol. 18, 6416–6422 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

78. Wan, C. K. et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38, 514–527 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

79. Wen, Z., Zhong, Z. & Darnell, J. E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241–250 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

80. Wen, Z. & Darnell, J. E. Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 25, 2062–2067 (1997).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

81. Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl Acad. Sci. USA 106, 9373–9378 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

82. Yang, J. et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 939–947 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

83. Yang, J. & Stark, G. R. Roles of unphosphorylated STATs in signaling. Cell Res. 18, 443–451 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar 

84. Hu, X. et al. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proc. Natl Acad. Sci. USA 110, 10213–10218 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

85. Gough, D. J. et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324, 1713–1716 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

86. Meier, J. A. & Larner, A. C. Toward a new STATe: the role of STATs in mitochondrial function. Semin. Immunol. 26, 20–28 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

87. Gadina, M. et al. Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13, 363–373 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

88. Shuai, K. & Liu, B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 5, 593–605 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

89. Kim, H. P., Imbert, J. & Leonard, W. J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17, 349–366 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar 

90. Heeb, L. E. M. & Boyman, O. Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment. Allergy 78, 1073–1087 (2022).

    Article 
    PubMed 

    Google Scholar 

91. Pandey, A. et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat. Immunol. 1, 59–64 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

92. Park, L. S. et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 192, 659–670 (2000).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

93. Ebina-Shibuya, R. & Leonard, W. J. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol. 23, 24–37 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

94. Rodeghiero, F. & Carli, G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann. Hematol. 96, 1421–1434 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

95. Kinch, M. S. An overview of FDA-approved biologics medicines. Drug Discov. Today 20, 393–398 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

96. Kieseier, B. C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 25, 491–502 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

97. Todd, P. A. & Goa, K. L. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 43, 111–122 (1992).

    Article 
    CAS 
    PubMed 

    Google Scholar 

98. Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13–25 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

99. Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M. & Schwarz, S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169–1188 (1985). Provides evidence that IL-2 in animal studies had translational potential as an antitumour therapeutic, with later approval by the FDA for metastatic melanoma and renal cell carcinoma.

    Article 
    CAS 
    PubMed 

    Google Scholar 

100. Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).

     Article 
     CAS 
     PubMed 

     Google Scholar 

101. Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167–178 (2002).

     Article 
     CAS 
     PubMed 

     Google Scholar 

102. Waldmann, T. A., Dubois, S., Miljkovic, M. D. & Conlon, K. C. IL-15 in the combination immunotherapy of cancer. Front. Immunol. 11, 868 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

103. Hinrichs, C. S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8⁺ T cells for adoptive immunotherapy. Blood 111, 5326–5333 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

104. Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8⁺ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

105. Harvill, E. T. & Morrison, S. L. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1, 95–105 (1995).

     Article 
     CAS 
     PubMed 

     Google Scholar 

106. Yao, Z., Dai, W., Perry, J., Brechbiel, M. W. & Sung, C. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol. Immunother. 53, 404–410 (2004).

     Article 
     CAS 
     PubMed 

     Google Scholar 

107. Glassman, C. R. et al. Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. eLife 10, e65777 (2021). Describes an IL-2 partial agonist that favours T_reg cell expansion.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

108. Mo, F. et al. An engineered IL-2 partial agonist promotes CD8⁺ T cell stemness. Nature 597, 544–548 (2021). Describes an IL-2 partial agonist that promotes a CD8⁺ T stem cell-like phenotype in vitro.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

109. Ishihara, A. et al. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat. Biomed. Eng. 5, 387–398 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

110. Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990).

     CAS 
     PubMed 

     Google Scholar 

111. Katre, N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144, 209–213 (1990).

     Article 
     CAS 
     PubMed 

     Google Scholar 

112. Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680–690 (2016).

     Article 
     CAS 
     PubMed 

     Google Scholar 

113. Sharma, M. et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun. 11, 661 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

114. Parisi, G. et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat. Commun. 11, 660 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

115. Dolgin, E. IL-2 upgrades show promise at ASCO. Nat. Biotechnol. 40, 986–988 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

116. Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288–1305 (2021).

     Article 
     PubMed 

     Google Scholar 

117. Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

118. Pires, I. S., Hammond, P. T. & Irvine, D. J. Engineering strategies for immunomodulatory cytokine therapies – challenges and clinical progress. Adv. Ther. 4, 100035 (2021).

     Google Scholar 

119. Nirschl, C. J. et al. Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression. Cancer Immunol. Res. 10, 581–596 (2022). Describes an IL-2 pro-drug that is activated by protease cleavage in the TME.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

120. Nirschl, C. J. et al. mWTX-330, an IL 12 INDUKINE molecule, activates and reshapes tumor-infiltrating CD8⁺ T and NK cells to generate antitumor immunity. Cancer Immunol. Res. https://doi.org/10.1158/2326-6066.CIR-22-0705 (2023).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

121. Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

122. Chiocca, E. A. et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

123. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927 (2006). A study using distinctive anti-IL-2 antibodies to stimulate intermediate- versus high-affinity IL-2 receptors, and differentially affecting T_reg cells and T_eff cells.

     Article 
     CAS 
     PubMed 

     Google Scholar 

124. Spangler, J. B. et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815–825 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

125. Spangler, J. B. et al. Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J. Immunol. 201, 2094–2106 (2018).

     Article 
     CAS 
     PubMed 

     Google Scholar 

126. Trotta, E. et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat. Med. 24, 1005–1014 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

127. Karakus, U. et al. Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci. Transl. Med. 12, eabb9283 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

128. VanDyke, D. et al. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 41, 111478 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

129. Arenas-Ramirez, N. et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci. Transl. Med. 8, 367ra166 (2016).

     Article 
     PubMed 

     Google Scholar 

130. Sahin, D. et al. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nat. Commun. 11, 6440 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

131. De Paula, V. S. et al. Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch. Proc. Natl Acad. Sci. USA 117, 7183–7192 (2020).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

132. Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037–1042 (2018). Describes the orthogonal IL-2/IL-2 receptor system.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

133. Hirai, T. et al. Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. J. Clin. Invest. 131, e139991 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

134. Aspuria, P. J. et al. An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci. Transl. Med. 13, eabg7565 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

135. Zhang, Q. et al. A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl. Med. 13, eabg6986 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

136. Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360–365 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

137. Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352–359 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

138. Collins, L. et al. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 85, 7709–7713 (1988).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

139. Sauve, K. et al. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 88, 4636–4640 (1991). Development of ‘no-α’ muteins of IL-2 that retain biological activity.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

140. Zurawski, S. M. et al. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 12, 5113–5119 (1993).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

141. Shanafelt, A. B. et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18, 1197–1202 (2000). Describes an early IL-2 mutein with antitumour activity in animal models.

     Article 
     CAS 
     PubMed 

     Google Scholar 

142. Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230–6238 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

143. Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1–14 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

144. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484, 529–533 (2012). Describes super-IL-2.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

145. Junttila, I. S. et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990–998 (2012).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

146. Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826–838 (2015). Describes an IL-2/IL-15 antagonist and IL-2 partial agonists.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

147. Strange, P. G. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br. J. Pharmacol. 153, 1353–1363 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

148. Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl Acad. Sci. USA 103, 2788–2793 (2006).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

149. Buchli, P. & Ciardelli, T. Structural and biologic properties of a human aspartic acid-126 interleukin-2 analog. Arch. Biochem. Biophys. 307, 411–415 (1993).

     Article 
     CAS 
     PubMed 

     Google Scholar 

150. Hermans, D. et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8⁺ T cell stemness and antitumor immunity. Proc. Natl Acad. Sci. USA 117, 6047–6055 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

151. Peng, M. et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354, 481–484 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

152. Carmenate, T. et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J. Immunol. 200, 3475–3484 (2018).

     Article 
     CAS 
     PubMed 

     Google Scholar 

153. Gaggero, S. et al. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein. Sci. Immunol. 7, eade5686 (2022). Describes a pH-selective mutein that is activated in the acidic TME.

     Article 
     CAS 
     PubMed 

     Google Scholar 

154. Gorby, C. et al. Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci. Signal. 13, eabc0653 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

155. Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

156. Glassman, C. R. et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell 184, 983–999 e924 (2021). Describes an approach for fine-tuning the signals of IL-12 and IL-23.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

157. Mendoza, J. L. et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature 567, 56–60 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

158. Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660–672 e669 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

159. Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399–409 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

160. Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719–729 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

161. Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537–547 (2002).

     Article 
     CAS 
     PubMed 

     Google Scholar 

162. Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17, 604–609 (2011).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

163. Rubinstein, M. P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl Acad. Sci. USA 103, 9166–9171 (2006).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

164. Mortier, E. et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281, 1612–1619 (2006).

     Article 
     CAS 
     PubMed 

     Google Scholar 

165. Desbois, M. et al. IL-15 trans-signaling with the superagonist RLI promotes effector/memory CD8⁺ T cell responses and enhances antitumor activity of PD-1 antagonists. J. Immunol. 197, 168–178 (2016). Describes a covalently linked IL-15–IL-15Rα super-agonist.

     Article 
     CAS 
     PubMed 

     Google Scholar 

166. Meghnem, D. et al. Cutting edge: differential fine-tuning of IL-2- and IL-15-dependent functions by targeting their common IL-2/15Rβ/γc receptor. J. Immunol. 198, 4563–4568 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

167. Burrack, K. S. et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural kαiller cells. Immunity 48, 760–772 e764 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

168. Wrangle, J. M. et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694–704 (2018). Describes ALT-803 (also known as N-803), an IL-15 super-agonist comprising IL-15(N72D) fused to dimeric IL-15Rα–IgG Fc.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

169. Seymour, C. FDA accepts BLA for N-803 in BCG-unresponsive non–muscle invasive bladder cancer in situ. Oncology Live Urologists in Cancer Care https://www.onclive.com/view/fda-accepts-bla-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-in-situ (1 August 2022).

170. Conroy, R. FDA declines N-803 combo approval in non-muscle invasive bladder cancer. Cancer Network https://www.cancernetwork.com/view/fda-declines-n-803-combo-approval-in-non-muscle-invasive-bladder-cancer (11 May 2023).

171. Rubinstein, M. P. et al. Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers. J. Immunol. 208, 1362–1370 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

172. Lowenthal, J. W. & Greene, W. C. Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor. J. Exp. Med. 166, 1156–1161 (1987).

     Article 
     CAS 
     PubMed 

     Google Scholar 

173. Lopes, J. E. et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J. Immunother. Cancer 8, e00673 (2020).

     Article 

     Google Scholar 

174. Ward, N. C. et al. Persistent IL-2 receptor signaling by IL-2/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms. Diabetes 69, 2400–2413 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

175. Hernandez, R. et al. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8⁺ T cells to enhance antitumor immunity. Cancer Immunol. Immunother. 70, 909–921 (2021). Describes a CD25–IL-2 fusion protein that favours formation of a trans-dimer, prolonging half-life; in models of lupus and type 1 diabetes, it favours expansion of T_reg cells but at high concentrations, it expands effector and memory T cell responses.

     Article 
     CAS 
     PubMed 

     Google Scholar 

176. Hernandez, R., LaPorte, K. M., Hsiung, S., Santos Savio, A. & Malek, T. R. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4⁺ and CD8⁺ neoantigen-specific T cells to promote antitumor immunity. J. Immunother. Cancer 9, e002865 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

177. Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186–191 (2019). Describes the ‘neokine’, NL-201, which is an IL-2/IL-15 mimetic.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

178. Hou, J. et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc. Natl Acad. Sci. USA 110, 3913–3918 (2013).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

179. Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020). Development of DR18, a variant of IL-18 that is resistant to inhibition by IL-18BP, an IL-18 decoy receptor.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

180. Padutsch, T. et al. Superior Treg-expanding properties of a novel dual-acting cytokine fusion protein. Front. Pharmacol. 10, 1490 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

181. Findeisen, M. et al. Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574, 63–68 (2019).

     Article 
     CAS 
     PubMed 

     Google Scholar 

182. Heuser, C. et al. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin’s lymphoma derived tumour cells. Int. J. Cancer 110, 386–394 (2004).

     Article 
     CAS 
     PubMed 

     Google Scholar 

183. Jahn, T. et al. An IL12-IL2-antibody fusion protein targeting Hodgkin’s lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS ONE 7, e44482 (2012).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

184. Martomo, S. A. et al. Single-dose anti-PD-L1/IL-15 fusion protein KD033 generates synergistic antitumor immunity with robust tumor-immune gene signatures and memory responses. Mol. Cancer Ther. 20, 347–356 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

185. Quayle, S. N. et al. CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin. Cancer Res. 26, 1953–1964 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

186. West, E. E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604–2615 (2013).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

187. Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8⁺ T cell exhaustion program. Nature 610, 173–181 (2022). Demonstrates that IL-2 and PD1 cooperate and that signalling via high-affinity receptors enhances antitumour immunity.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

188. Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8⁺ T cells. Nature 610, 161–172 (2022). Describes the PD1–IL-2v immunokine that maintains stem-like CD8⁺ cells with enhanced antitumour activity.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

189. Harris, K. E. et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci. Rep. 11, 10592 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

190. Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430 e1419 (2022). Shows an approach to rapidly discover new cytokine agonists.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

191. Waldmann, T. A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26, 3699–3703 (2007).

     Article 
     CAS 
     PubMed 

     Google Scholar 

192. Bielekova, B. et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl Acad. Sci. USA 101, 8705–8708 (2004).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

193. Tanaka, T., Narazaki, M. & Kishimoto, T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028456 (2017).

     Article 

     Google Scholar 

194. Narazaki, M. & Kishimoto, T. Current status and prospects of IL-6-targeting therapy. Expert. Rev. Clin. Pharmacol. 15, 575–592 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

195. Huseni, M. A. et al. CD8⁺ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

196. Shirley, M. Dupilumab: first global approval. Drugs 77, 1115–1121 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

197. van Vollenhoven, R. F. et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 72, 761–768 (2020).

     Article 
     PubMed 

     Google Scholar 

198. Hoy, S. M. Tezepelumab: first approval. Drugs 82, 461–468 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

199. Le Floc’h, A. et al. Blocking common gamma chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models. Sci. Transl. Med. 15, eabo0205 (2023).

     Article 
     PubMed 

     Google Scholar 

200. Liu, S. et al. A synthetic human antibody antagonizes IL-18Rbeta signaling through an allosteric mechanism. J. Mol. Biol. 432, 1169–1182 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

201. Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857–3876 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

202. Rajala, H. L., Porkka, K., Maciejewski, J. P., Loughran, T. P. Jr & Mustjoki, S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann. Med. 46, 114–122 (2014).

     Article 
     CAS 
     PubMed 

     Google Scholar 

203. Kucuk, C. et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat. Commun. 6, 6025 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

204. Forbes, S. A. et al. COSMIC: high-resolution cancer genetics using the catalogue of somatic mutations in cancer. Curr. Protoc. Hum. Genet. https://doi.org/10.1002/cphg.21 (2016).

     Article 
     PubMed 

     Google Scholar 

205. Miklossy, G., Hilliard, T. S. & Turkson, J. Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 12, 611–629 (2013).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

206. Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

207. Toniolo, P. A. et al. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J. Immunol. 194, 3180–3190 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

208. Elumalai, N. et al. Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b. Sci. Rep. 7, 819 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

209. Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

210. Garber, K. The PROTAC gold rush. Nat. Biotechnol. 40, 12–16 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

211. Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498–511 e417 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

212. Shah, R. R. et al. Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs. Bioorg. Med. Chem. 28, 115326 (2020). Development of PROTACs.

     Article 
     CAS 
     PubMed 

     Google Scholar 

213. Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273–281 (2023).

     Article 
     CAS 
     PubMed 

     Google Scholar 

214. Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

215. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

216. Ptacin, J. L. et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat. Commun. 12, 4785 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

217. Tchao, N. et al. Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study. Ann. Rheum. Dis. 81, 1343–1344 (2022).

     Article 

     Google Scholar 

218. Laurent, J. et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J. Transl. Med. 11, 5 (2013).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

219. Merchant, R. et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. J. Immunother. Cancer 10, e003155 (2022).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

220. Emmerich, J. et al. STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Res. 81 (Suppl. 13), 1744 (2021).

     Article 

     Google Scholar 

221. Waldhauer, I. et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 13, 1913791 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

222. Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

223. Fishman, M. N. et al. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin. Cancer Res. 17, 7765–7775 (2011).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

224. Moynihan, K. D. et al. AB248 is a CD8⁺ T cell selective IL-2 designed for superior safety and anti-tumor efficacy [abstract]. Cancer Res. 82 (Suppl. 12), 3518 (2022).

     Article 

     Google Scholar 

225. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/search?term=NCT04710043 (2023).

226. DeOca, K. B., Moorman, C. D., Garcia, B. L. & Mannie, M. D. Low-zone IL-2 signaling: fusion proteins containing linked CD25 and IL-2 domains sustain tolerogenic vaccination in vivo and promote dominance of FOXP3⁺ Tregs in vitro. Front. Immunol. 11, 541619 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

227. McKean, M. et al. A first-in-human, multicenter, phase 1/2 open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solids tumors [abstract]. J. Clin. Oncol. 40 (Suppl. 16), TPS2697 (2022).

     Article 

     Google Scholar 

228. Fischer, R. et al. Selective activation of tumor necrosis factor receptor ii induces antiinflammatory responses and alleviates experimental arthritis. Arthritis Rheumatol. 70, 722–735 (2018).

     Article 
     CAS 
     PubMed 

     Google Scholar 

229. Miyazaki, T. et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. J. Immunother. Cancer 9, e002024 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

230. Zhu, X. et al. Novel human interleukin-15 agonists. J. Immunol. 183, 3598–3607 (2009).

     Article 
     CAS 
     PubMed 

     Google Scholar 

231. Liu, B. et al. A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J. Biol. Chem. 291, 23869–23881 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

232. Conlon, K. et al. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. J. Immunother. Cancer 9, e003388 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

233. Tredan, O. et al. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4⁺ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann. Oncol. 26, 1353–1362 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

234. Lim, J. Y. et al. Biophysical stability of hyFc fusion protein with regards to buffers and various excipients. Int. J. Biol. Macromol. 86, 622–629 (2016).

     Article 
     CAS 
     PubMed 

     Google Scholar 

235. Sohn, J. et al. Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): the KEYNOTE-899 study [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 1081–1081 (2022).

     Google Scholar 

236. Sun, J. C., Lehar, S. M. & Bevan, M. J. Augmented IL-7 signaling during viral infection drives greater expansion of effector T cells but does not enhance memory. J. Immunol. 177, 4458–4463 (2006).

     Article 
     CAS 
     PubMed 

     Google Scholar 

237. Hsieh, J. et al. A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. Clin. Transl. Immunol. 4, e37 (2015).

     Article 

     Google Scholar 

238. Dower, W. et al. MDK1319/MDK-701: a potent fully efficacious peptidyl agonist of IL-7R alpha gamma C, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an FC-domain for PK enhancement. J. Immunother. Cancer 8, A341–A342 (2020).

     Google Scholar 

239. Friend, R., Baxter, B., Park, I. A., Cwirla, S. & Barrett, R. A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of Mdk-703, an Il-7 mimetic with extended half-life. J. Immunother. Cancer 10, A657 (2022).

     Google Scholar 

240. Song, Y. et al. In vivo antitumor activity of a recombinant IL7/IL15 hybrid cytokine in mice. Mol. Cancer Ther. 15, 2413–2421 (2016).

     Article 
     CAS 
     PubMed 

     Google Scholar 

241. Morello, A. et al. A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity [abstract]. Cancer Res. 80 (Suppl. 16), 910 (2020).

     Article 

     Google Scholar 

242. Shen, S. et al. Engineered IL-21 cytokine muteins fused to anti-PD-1 antibodies can improve CD8⁺ T cell function and anti-tumor immunity. Front. Immunol. 11, 832 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

243. Li, Y. et al. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nat. Commun. 12, 951 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

244. Bhatt, S. et al. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood 129, 2246–2256 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

245. Sampson, J. H. et al. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: results of a phase 2b trial. Neuro Oncol. 25, 1085–1097 (2023).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

246. Kim, Y. H. et al. A single-arm phase 2A study of NM-IL-12 (rHu-IL12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT) [abstract]. Blood 128, 4165 (2016).

     Article 

     Google Scholar 

247. Gutierrez, E. et al. An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med 4, 326–340.e5 (2023).

     Article 
     CAS 
     PubMed 

     Google Scholar 

248. Strauss, J. et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin. Cancer Res. 25, 99–109 (2019).

     Article 
     CAS 
     PubMed 

     Google Scholar 

249. Greiner, J. W., Morillon, Y. M. 2nd & Schlom, J. NHS-IL12, a tumor-targeting immunocytokine. Immunotargets Ther. 10, 155–169 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

250. Ongaro, T. et al. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. J. Biotechnol. 291, 17–25 (2019).

     Article 
     CAS 
     PubMed 

     Google Scholar 

251. Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827–839 (1998).

     Article 
     CAS 
     PubMed 

     Google Scholar 

252. Bazan, J. F. Neuropoietic cytokines in the hematopoietic fold. Neuron 7, 197–208 (1991).

     Article 
     CAS 
     PubMed 

     Google Scholar 

253. Martins, G. A., Cimmino, L., Liao, J., Magnusdottir, E. & Calame, K. Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J. Exp. Med. 205, 1959–1965 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

254. Tomkowicz, B. et al. TIM-3 suppresses anti-CD3/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway. PLoS ONE 10, e0140694 (2015).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

255. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061 (2003).

     Article 
     CAS 
     PubMed 

     Google Scholar 

256. Li, P. et al. STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: functional dissection of the Il2ra gene locus. Proc. Natl Acad. Sci. USA 114, 12111–12119 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

257. Simeonov, D. R. et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature 549, 111–115 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

258. Xu, X., Sun, Y. L. & Hoey, T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 273, 794–797 (1996).

     Article 
     CAS 
     PubMed 

     Google Scholar 

259. Vinkemeier, U. et al. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J. 15, 5616–5626 (1996).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

260. John, S., Vinkemeier, U., Soldaini, E., Darnell, J. E. Jr. & Leonard, W. J. The significance of tetramerization in promoter recruitment by Stat5. Mol. Cell Biol. 19, 1910–1918 (1999).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

261. Vahedi, G. et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520, 558–562 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

262. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

263. Godfrey, V. L., Wilkinson, J. E. & Russell, L. B. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 138, 1379–1387 (1991).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

264. Blair, P. J. et al. CD4⁺CD8⁻ T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J. Immunol. 153, 3764–3774 (1994).

     Article 
     CAS 
     PubMed 

     Google Scholar 

265. Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541–566 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

266. Yu, A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172–2183 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

267. Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).

     Article 
     CAS 
     PubMed 

     Google Scholar 

268. Mizui, M. & Tsokos, G. C. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front. Immunol. 9, 786 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

269. He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991–993 (2016).

     Article 
     CAS 
     PubMed 

     Google Scholar 

270. He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141–149 (2020). Efficacy of low-dose IL-2 related to systemic lupus erythematosis.

     Article 
     CAS 
     PubMed 

     Google Scholar 

271. von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407–1415 (2016).

     Article 

     Google Scholar 

272. Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295–305 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

273. Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J. Autoimmun. 58, 48–58 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

274. Rosenzwajg, M. et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 63, 1808–1821 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

275. Dong, S. et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 6, e147474 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

Download references